BIRC5 and prostate carcinoma: Positive immunostaining was recognized in 5347 prostate carcinomas with 58.8% cytoplasmic, 35.6% apical, and 5.7% nuclear localization and considered strong in 16.1%, moderate in 33.8%, and weak in 50.0% of survivin‐positive cancers.